18:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

TG Therapeutics reports Phase II data for umbralisib in CLL

TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib (TGR-1202) led to nodal reductions in nearly all patients evaluable for response, including three patients with complete resolution of nodal disease, in a Phase II trial to...
20:43 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Imlygic meets ORR endpoint in Phase II melanoma trial

Amgen Inc. (NASDAQ:AMGN) reported data from the Phase II portion of the Phase Ib/II '264 trial in 198 patients with unresectable stage IIIB-IV melanoma showing that intratumoral Imlygic talimogene laherparepvec plus Yervoy ipilimumab met the...
08:00 , Feb 22, 2016 |  BioCentury  |  Emerging Company Profile

Oncolytic immunotherapy

Turnstone Biologics Inc. is combining an oncolytic virus with cancer vaccines, which it anticipates will result in products with efficacy advantages over each individual modality. Turnstone's origins trace to the Ottawa Hospital Research Institute...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

TGR-1202: Additional Phase I data

Data from 63 evaluable patients with relapsed or refractory hematologic malignancies in an open-label, U.S. Phase I trial showed that once-daily oral TGR-1202 at doses of 800-1,800 mg in an initial formulation and 200-1,200 mg...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the...
08:00 , Dec 14, 2015 |  BioCentury  |  Finance

ASH to ashes

Fueled by the emergence of data on gene therapies and CAR T therapies for hematologic diseases a year ago, investors have now begun to watch ASH milestones as closely as they have always watched ASCO....
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Imlygic talimogene laherparepvec: Phase Ib data

Data from 16 evaluable patients with previously untreated, unresected advanced melanoma in the open-label, international Phase Ib MASTERKEY-265 trial showed that 200 mg Keytruda pembrolizumab every 2 weeks plus Imlygic talimogene laherparepvec led to...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Keytruda pembrolizumab: Phase Ib data

Data from 16 evaluable patients with previously untreated, unresected advanced melanoma in the open-label, international Phase Ib MASTERKEY-265 trial showed that 200 mg Keytruda pembrolizumab every 2 weeks plus Imlygic talimogene laherparepvec led to...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

T-Vec talimogene laherparepvec: Additional Phase III data

The open-label, international Phase III OPTiM trial in 436 patients with stage IIIb-IV melanoma showed that Imlygic led to a DRR, the primary endpoint defined as the rate of CR or PR lasting continuously for...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Talimogene laherparepvec regulatory update

FDA approved a BLA from Amgen for Imlygic talimogene laherparepvec for local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma that is recurrent after initial surgery. It is the first FDA...